论文部分内容阅读
Mifepristone(RU486)is marketed and used widely by women as an abortifacient,and used in clinical trials for psychotic depression and anticancer treatments.Metapristone is the most predominant biological active metabolite of mifepristone.In recent year,the study show that metapristone has the effect of preventing of tumor metastasis,which may be a good candidate drug to prevent tumor metastasis.Therefore,the purpose of our study was to investigate gender-related differences in pharmacokinetics of mifepristone or metapristone in the rat and beagle dogs and to study the mechanisms of action by which the gender difference in metapristone pharmacokinetics.